SlideShare a Scribd company logo
1 of 8
Download to read offline
BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS




WEDNESDAY                                                                                                                             VOLUME 22 , NO. 41
MARCH 2, 201 1                                                                                                                               PAGE 1 OF 8

‘Buy American’                                                                    FDA OKs Narrower Indication
Daiichi Sankyo Bolsters Pipe                                                      for Forest Lab’s COPD Drug
with $935M Plexxikon Buy                                                          By Marie Powers
By Tom Wall                                                                       BioWorld Today Contributing Writer
Staff Writer                                                                           After a long and winding road, the FDA has at last given
     In the latest acquisition of a U.S. biotech with promising                   Forest Laboratories Inc. the green light to market Daliresp
oncology offerings by a Japanese company, Daiichi Sankyo                          (roflumilast) in the U.S. to reduce the risk of chronic
Co. Ltd., of Tokyo, bought Plexxikon Inc., of Berkeley, Calif.,                   obstructive pulmonary disease (COPD) exacerbations
and its promising melanoma drug PLX4032, for $805 million                         in patients with severe COPD associated with chronic
up front and near-term milestones of $130 million linked to                       bronchitis and a history of such flare-ups, which may
approval of PLX4032.                                                              include breathlessness, chronic cough and excessive
     In recent years, Japanese drugmakers have made a                             production of phlegm leading to medical intervention,
series of major U.S. oncology buys, including Eisai Co.’s $205                    including hospitalization.
million September 2006 purchase of Ligand Pharmaceuticals                              In 2009, New York-based Forest licensed the drug –
Inc.’s three-drug cancer portfolio, a $325 million buyout of                      marketed as Daxas in the European Union and Canada
Morphotek in March 2007 and, earlier this year, $200 million                      – from privately held Nycomed GmbH, of Zurich,
in research funding to start-up H3 Biomedicine; Takeda                            Switzerland, in a deal potentially worth more than $500
Pharmaceutical Co.’s $8.8 billion purchase of Millennium                          million. (See BioWorld Today, Aug. 11 , 2009.)
Pharmaceuticals Inc. in April 2008; and Astellas Pharma                                Nycomed had initially submitted the new drug
                                               See Plexxikon, Page 2                                                                See Forest, Page 4


Novavax, VaxInnate Get                                                            Financings Roundup

Welcome Shot in the Arm                                                           Investors to the Rescue as
By Mari Serebrov                                                                  Tengion Pulls in $31M PIPE
Washington Editor                                                                 By Jennifer Boggs
     WASHINGTON – Two government contracts that could be                          Assistant Managing Editor
worth up to nearly $200 million each will inoculate Novavax                            After a roller coaster February, in which shares of
Inc. and VaxInnate Inc. against some of the financial risks                        Tengion Inc. rose on buyout speculation only to fall after
involved in getting their recombinant influenza vaccines                           the surge in trading activity scared off a potential acquirer,
through clinical development.                                                     investors of the East Norriton, Pa.-based regenerative
     The cost-reimbursable, milestone-based contracts,                            medicine firm have stepped up with some much-needed
awarded by the Department of Health and Human Services                            financing.
(HHS), are for three years with a possible two-year extension.                         Tengion is bringing in $31 .4 million in a PIPE transaction
Novavax, of Rockville, Md., will receive $97 million over                         in exchange for issuing about 1 1 . 1 million shares of common
the first three years, which is enough to bring its seasonal                       stock and warrants to purchase about 10.5 million shares
influenza recombinant virus-like particle (VLP) vaccine                            to certain investors. One of those investors is Medtronic
through late-stage trials to FDA licensure, John Trizzino,                        Inc., a Minneapolis-based medical device company that
Novavax senior vice president of business development,                            picked up, in exchange, a right of first refusal on the
told investors Tuesday.                                                           preclinical Neo-Kidney Augment program through Oct. 31,
     If the extension is granted, the total contract would                        2013.

                                               See Influenza, Page 5                                              See Financings Roundup, Page 6




INSIDE:               OTHER NEWS TO NOTE: GERON, INSMED, IRX THERAPEUTICS, KENPHARM .....7
                      CLINIC ROUNDUP: SEATTLE GENETICS, SYNDAX, TOBIRA THERAPEUTICS ...........8
                 To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.
                          Copyright © 2011 AHC Media. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
WEDNESDAY, MARCH 2, 201 1                                          BIOWORLD® TODAY                                                              PAGE 2 OF 8


Plexxikon
Continued from page 1
Inc.’s $4 billion acquisition of OSI in May 2010 and several                              Coming Thursday in
deals leading up to it.                                                                  BioWorld Perspectives:
     The pattern is not a coincidence, Plexxikon CEO K.
Peter Hirth told BioWorld Today, but rather how Japanese                                              ‘All My Clones,’
companies must compete because of a shortage of biotech                                   BioWorld’s Biotech-Themed Soap Opera
innovation in Japan.
     “It’s particularly true in oncology,” Hirth said. “The                            In this week’s “All My Clones,” read about Cappuccino
innovation gap in Japanese pharma in the last 10 years is just                    Pharmaceuticals’ plans to investigate placebos and
mind boggling. There is not enough innovation happening                           some unethical actions by board members. If you
in Japan by itself. They have to buy it. Biotech did not take off                 missed previous episodes of BioWorld’s biotech-themed
in Japan. It has been a big challenge for the Japanese.”                          soap opera, look to the top of the story for a link to the
     PLX4032 captured the attention of the cancer world                           “All My Clones” archives.
during the past year and a half. Most recently, an interim
analysis of a Phase III trial released in January showed both                         BioWorld Perspectives is a weekly e-zine that
an overall survival benefit and a progression-free survival                        offers unique viewpoints on developments within
benefit for patients taking the drug as a first-line agent. (See                    the biotechnology industry. And the best part is, it’s
BioWorld Today, Jan. 20, 2011 , and Nov. 8, 2010.)                                completely free. Opt-in at www.bioworld.com.
     The 675-patient BRIM 3 study was the first where
PLX4032, which also goes by the name RG7204, was used
as a first-line agent for BRAF mutation positive metastatic
melanoma. Patients were randomized to receive either oral
PLX4032 twice daily, or the current standard of care, which
consists of intravenous dacarbazine every three weeks.
                                                                                                       Stock Movers
Hirth said at the time the data were so strong that the study                                                   03/01/1 1
was terminated early, and patients in the control arm have                               Company                                 Stock Change
been given the option to cross over onto PLX4032.
     Plexxikon, a privately held firm, and development                                  Nasdaq Biotechnology                     -$6.44     -0.7%
partner Roche AG, planned to file for market approval                                   Novavax Inc.                             +$0.36 +13.9%
in the U.S. and Europe this year, along with a filing for the
companion diagnostic also being co-developed by the                                    Repros Therapeutics Inc.                  +$1 .29 +28.7%
partners. It is an extremely quick progression. The Phase I                            RXi Pharmaceuticals Corp.                -$0.47 -27.7%
trial of PLX4032 began in December 2006. The results of that                           Vivus Inc.                               -$0.83    -10.9%
trial, which were published in 2010, prompted Plexxikon and
Roche to move the drug directly into pivotal testing. The first
patient was enrolled in the BRIM3 study in January 2010.                               (Biotechs showing significant stock changes Tuesday)

                                                See Plexxikon, Page 3

                                                                                                              SUBSCRIBER INFORMATION
 BioWorld® Today (ISSN# 1541-0595) is published every business day by AHC Media, 3525 Piedmont Road,
 Building Six, Suite 400, Atlanta, GA 30305 U.S.A. Opinions expressed are not necessarily those               Please call (800) 688-2421 to subscribe or if
 of this publication. Mention of products or services does not constitute endorsement. BioWorld® and Bio-     you have fax transmission problems. Outside
 World® Today are trademarks of AHC Media, a Thompson Publishing Group company. Copyright © 2011              U.S. and Canada, call (404) 262-5476. Our
 AHC Media. All Rights Reserved. No part of this publication may be reproduced without the written con-       customer service hours are 8:30 a.m. to 6:00
 sent of AHC Media. (GST Registration Number R128870672).                                                     p.m. EST.
                                                                                                              Lynn Yoffee, (404) 262-5408
 ATLANTA NEWSROOM: Managing Editor: Lynn Yoffee. Assistant Managing Editor: Jennifer Boggs.
                                                                                                              Jennifer Boggs, (404) 262-5427
                          Senior Staff Writer: Karen Pihl-Carey. Senior Production Editor: Ann Duncan.
                          Staff Writer: Tom Wall.                                                             Anette Breindl, (518) 595-4041
                                                                                                              Trista Morrison, (858) 901-4785
 WASHINGTON BUREAU: Washington Editor: Mari Serebrov.                                                         Mari Serebrov, (703) 678-7376
 WEST COAST BUREAU: Staff Writer: Trista Morrison.                                                            Tom Wall, (404) 262-5417
 EAST COAST BUREAU: Science Editor: Anette Breindl.
 BUSINESS OFFICE:         Senior Vice President/Group Publisher: Donald R. Johnston.                          Senior Vice President/Group Publisher:
                          Director of Product Management: Jane Cazzorla.                                      Donald R. Johnston, (404) 262-5439
                          Marketing Manager: Sarah Cross.                                                     Internet: http://www.bioworld.com
                          Account Representatives: Matt Hartzog, Chris Wiley, Scott Robinson.
 DISPLAY ADVERTISING: For ad rates and information, please call Stephen Vance at (404) 262-5511
                          or email him at stephen.vance@ahcmedia.com.
 REPRINTS:                For photocopy rights or reprints, call our reprints department at (404) 262-5479.
 PRESS MATERIALS:         Send all press releases and related information to newsdesk@bioworld.com.
WEDNESDAY, MARCH 2, 201 1                                        BIOWORLD® TODAY                                                           PAGE 3 OF 8

Plexxikon                                                                     for pancreatic cancer. (See BioWorld Today, Sept. 11, 2006, and
Continued from page 2                                                         March 23, 2007.)
      Plexxikon has an agreement to co-promote PLX4032                              In January of this year, Eisai Inc., of Woodcliff Lake, N.J.,
in the U.S. with Roche’s U.S. commercial oncology                             the U.S. pharmaceutical operation of Tokyo-based Eisai Co.
unit, Genentech. Daiichi Sankyo will retain the U.S. co-                      pledged as much as $200 million in research funding to
promotion rights for PLX4032. Hirth said that he expects                      start-up H3 Biomedicine, of Cambridge, Mass., which hopes
co-promotion will be, “pretty straightforward. It will just                   to develop oncology treatments genetically tailored to
be shared. Everybody knows everybody, and everybody is                        patients’ cancers. (See BioWorld Today, Jan. 31 , 2011 .)
comfortable.”                                                                       Takeda, of Osaka, acquired Millennium Pharmaceuticals
      Hirth said Plexxikon will continue on with similar                      Inc., of Cambridge, Mass., and its lucrative Velcade multiple
staff and budget. “They like the way we have developed                        myeloma product in April 2008 for $8.8 billion, renaming
projects, and they expect to get a number of additional                       the company Millennium: The Takeda Oncology Co. (See
development candidates,” he said, describing the 40-plus                      BioWorld Today, April 11, 2008.)
person Plexxikon team as “good size, working well, a fine-                           Astellas, of Tokyo, bought OSI, of Melville, N.Y., for $4
tuned racing engine.”                                                         billion in May 2010, boosting its oncology franchise and
      PLX4032, an orally active kinase inhibitor that targets                 adding OSI’s blockbuster cancer drug Tarceva (erlotinib) as
an activating BRAF mutation, is also an example of the                        well as a U.S. sales force, a pipeline of small molecules and
power of personalized medicine. The drug is being co-                         discovery capabilities. (See BioWorld Today, May 18, 2010.)
developed with a diagnostic test to identify patients whose                         A series of smaller deals led up to the OSI acquisition.
tumors carry the V600 mutation. Such mutations account                        In December 2007 Astellas bought Agensys Inc., of Santa
for about half of all melanoma cases.                                         Monica, Calif., and a pipeline of early clinical-stage anticancer
      The extremely rapid hurtle down the clinical                            antibodies for $537 million; licensed prostate cancer drug
development path also means that the conclusions about                        MDV3100 in a $765 million deal with Medivation Inc., of
PLX4032’s safety and efficacy are based on relatively                          San Francisco, in October 2009; and in December 2009 got
few patients, and relatively few clinical events. Such                        acute myeloid leukemia drug AC220 in a potential $390
small numbers and statistics can be shaky, but Plexxikon                      million deal with Ambit Biosciences Corp., of San Diego.
executives have said that because of the strength of the                            If U.S. oncology biotechs have attracted attention from
data, they are not concerned that the sample size is small.                   Japanese companies, so too, have selective kinase inhibitors
      Melanoma has proved a tough disease for drug                            been in the spotlight of late. (See BioWorld Insight, Feb. 28,
developers in the past, with notable failures such as Genta                   2011 .)
Inc.’s Bcl-2 targeting antisense drug Genasense (oblimersen)                        Gilead Sciences Inc.’s recent buyout of Calistoga
and tyrosine kinase inhibitor Nexavar (sorafenib) from                        Pharmaceuticals Inc. for $375 million in cash and up to
Onyx Pharmaceuticals Inc. and Bayer AG. But there have                        $225 million in milestones for rights to PI3K delta isoform
been bright spots in the space of late, with Bristol-Myers                    CAL-101 underscores the enthusiasm for small-molecule
Squibb Co.’s ipilimumab, acquired through its acquisition of                  kinase inhibition. A week earlier AVEO Pharmaceuticals Inc.
Medarex Inc., showing promising survival data in a pivotal                    signed a potential $1 billion-plus partnership for tivozanib,
study. (See BioWorld Today, June 8, 2010, and Nov. 8, 2010.)                  a Phase III-stage kinase inhibitor targeting VEGFR 1 , 2 and 3.
      Joji Nakayama, CEO of Daiichi Sankyo Co. Ltd., said                     (See BioWorld Today, Feb. 17, 2011 , and Feb. 23, 2011 .)
in a statement that his company sees the acquisition of                             Kinase inhibitors have produced blockbusters like
Plexxikon as an opportunity to accelerate the building of                     Gleevec (imatinib, Novartis AG) and near-blockbusters like
the company’s oncology franchise.                                             Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer
      Other major Japanese pharma firms, including Eisai,                      AG) and Sutent (sunitinib, Pfizer Inc.). ■
Takeda and Astellas, have preceded Daiichi Sankyo with the
“buy American” oncology strategy.
      Eisai in September 2006 purchased a three-drug cancer                                Clinic Roundup
portfolio – Ontak (denileukin diftitox), for cutaneous T-cell
lymphoma; Targretin (bexarotene) gel and capsules, also for                        • Cytheris SA, of Paris, said a Phase IIa study of its
CTCL; and Panretin (alitretinoin) gel for Kaposi’s sarcoma, an                HIV candidate, CYT109 (interleukin-7), provided evidence
AIDS-related skin cancer – from Ligand Pharmaceuticals Inc., of               of efficacy and showed that interleukin-7 stimulated the
San Diego, for $205 million plus royalties. Eisai next acquired               expansion of CD4 and CD8 T cells in peripheral blood.
Morphotek, Inc., of Exton, Pa., in March 2007 in a $325 million               Those results showed that interleukin-7 was important in
buyout. One of a few firms at the time that could make fully                   stimulating T-cell repopulation of lymphoid tissue in the
human monoclonal antibodies in cell culture, Morphotek had                    GI tract. Cytheris presented the data at the 2011 Conference
a pair of clinical-stage drug candidates, MORAb 003, in Phase                 on Retroviruses and Opportunistic Infections being held in
I/II trials for ovarian cancer, and MORAb 009, in Phase I trials              Boston this week.

               To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.
                        Copyright © 2011 AHC Media. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
WEDNESDAY, MARCH 2, 201 1                                        BIOWORLD® TODAY                                                           PAGE 4 OF 8

Forest                                                                        warnings, but the FDA did not require a black-box warning
Continued from page 1                                                         for the drug.
application for roflumilast in July 2009 with a proposed                            The company expects Daliresp to be available to
indication as a maintenance treatment of COPD associated                      wholesalers in the second calendar quarter.
with chronic bronchitis in patients at risk of exacerbations.                      Patients with COPD have largely depended on inhalers
Last spring, however, FDA reviewers voiced concerns over                      to treat symptoms of the disease, so the approval of
suicides linked to the drug. (See BioWorld Today, April 6, 2010.)             Daliresp “is good news for [Forest] and validates the
     Subsequently, the FDA’s Pulmonary-Allergy Drugs                          company as differentiated from a regulatory perspective,”
Advisory Committee reversed its earlier endorsement of                        Leerink Swann Healthcare Equity Research analyst Seamus
the drug, voting against the drug’s approval. (See BioWorld                   Fernandez wrote in a research note.
Today, April 8, 2010.)                                                             Jefferies & Co. analyst Corey Davis was even
     Thus, it was hardly a surprise when the agency issued                    more ebullient, describing Daliresp as “Forest’s most
a complete response letter for roflumilast. (See BioWorld                      underappreciated pipeline drug” and predicting “blockbuster-
Today, May 19, 2010.)                                                         like potential” for the drug. “We’ve seen the label and it looks
     In the midst of the FDA’s review, Forest had submitted                   great,” Davis wrote in a research note. “While there are
a new application – too late in the game to be considered                     some warnings, there are no black-box warnings, no [risk
originally by the FDA panel – for the narrower indication                     evaluation and mitigation strategy], and as we expected, use
and a new warning about neuropsychiatric events. At the                       is being restricted to the most severe patients.”
time, analysts suggested the changes would pass muster                             Though Forest has not disclosed pricing information,
with the FDA, which turned out to be the case.                                Davis expects Daliresp to be priced competitively with
     Officials at Forest were traveling and did not respond to                 Spiriva (tiotropium bromide, Pfizer Inc.).
requests for an interview.                                                         “Because of Daliresp’s unique mechanism of action, we
     Daliresp, an oral tablet taken once daily, becomes the                   don’t see it competing directly vs. the inhalers, and as an
first FDA-approved selective phosphodiesterase-4 inhibitor.                    oral med, we see great utility as a potential combo agent,”
The compound’s specific mechanism of therapeutic action                        Davis wrote. Although the “consensus” 2016 Street estimate
in COPD is not well defined, but is thought to be related to                   for Daliresp is $292 million, compared to Jefferies’ $523
the effects of increased intracellular cyclic AMP in lung cells.              million estimate, “with Forest likely to go ‘whole hog’ on
     Forest said the efficacy and safety of Daliresp were                      the Daliresp launch, and use of the drug likely to move
evaluated in eight clinical studies including 9,394 adult                     upstream into milder COPD patients, we think our estimates
patients. Of these, 4,425 were treated with Daliresp 500 mcg.                 could prove to be conservative,” he added.
     Two one-year trials enrolled patients with severe COPD                        Although shares of Forest (NYSE:FRX) gained more than
associated with chronic bronchitis, at least one COPD                         $1 before the market opened Tuesday, sending the stock
exacerbation in the previous year and at least a 20 pack-                     from Monday’s close of $32.40 to $33.64 at Tuesday’s
year smoking history. In these trials, long-acting beta-                      opening bell, the stock lost ground during another brutal
agonists and short-acting anti-muscarinics were used by                       day for the market, closing at $32.02, down 38 cents. ■
44 percent and 35 percent of patients treated with Daliresp
and 45 percent and 37 percent of patients treated with
placebo, respectively.                                                                  Other News To Note
     One of these trials randomized 1 ,525 patients (765 on
Daliresp) and the other randomized 1 ,571 patients (772 on                         • Genzyme Corp., of Cambridge, Mass., completed
Daliresp). Daliresp reduced the rate of moderate or severe                    the sale of its pharmaceutical intermediates business
exacerbations, compared to placebo, by 15 percent in one                      to International Chemical Investors Group (ICIG). The
trial and by 18 percent in the other.                                         acquired business, which includes all but the drug
     The most common adverse reactions, occurring in less                     delivery technologies portion, has been renamed Corden
than or equal to 10 percent of patients receiving Daliresp                    Pharma Switzerland LLC and will operate as part of ICIG’s
in the eight trials, included diarrhea, nausea, weight loss,                  pharmaceutical business within the Corden Pharma group.
headache, back pain, influenza, insomnia, dizziness and                        Financial terms are not material to Genzyme and were
decreased appetite. Daliresp was associated with an                           not disclosed. As part of the agreement, Corden Pharma
increase in psychiatric adverse reactions (5.9 percent of                     contracted with Genzyme to provide materials needed
patients treated with Daliresp vs. 3.3 percent treated with                   for the production of eliglustat tartrate, an investigational
placebo). During clinical trials, the company said one patient                treatment for Gaucher disease Type 1 that’s in Phase III
treated with Daliresp committed suicide and two attempted                     trials, and for the manufacture of other treatments. The
suicide, compared to one patient treated with placebo who                     sale completes the three divestitures announced last year
considered suicide.                                                           as part of Genzyme’s effort to sharpen its focus on core
     The risk of suicide is mentioned among the label                         businesses. (See BioWorld Today, July 22, 2010.)

               To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.
                        Copyright © 2011 AHC Media. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
WEDNESDAY, MARCH 2, 201 1                                        BIOWORLD® TODAY                                                           PAGE 5 OF 8

Influenza                                                                          LGLS will be responsible for conducting clinical trials
Continued from page 1                                                         and getting the vaccines licensed in these areas. Novavax
be $179. 1 million. The additional funding would support                      will provide technology transfer and manufacturing support
three Phase I and II trials of a pandemic H5N1 VLP vaccine,                   for a manufacturing facility LGLS is building in South Korea.
Trizzino added.                                                                    Novavax will receive an up-front payment with potential
     VaxInnate, of Cranbury, N.J., will receive $117.9 million                milestones, Singhvi said. It also will receive double-digit
over the first three years, which can be extended for                          royalty payments from LGLS’ commercial sales of VLP
a total contract value of $196.6 million. The five-year                        vaccines in South Korea and the emerging markets. Terms
funding would enable the privately held company to take                       of those payments were not disclosed.
its seasonal and pandemic influenza vaccines up through                             At VaxInnate, the HHS contract will “put the company on
Phase III development.                                                        more solid footing” as it begins the long process of clinical
     “This gives us the financial security to carry out this                   trials for its pandemic and seasonal flu vaccines, Seth
kind of long-haul development program,” Alan Shaw,                            Rudnick, a physician, venture partner at Canaan Partners,
VaxInnate’s chief scientific officer, told BioWorld Today. “It                  and board member of VaxInnate, told BioWorld Today.
allows us to breathe.”                                                             Canaan invested in VaxInnate four years ago to support
     For Novavax, news of the HHS contract came on the                        the development of a vaccine technology with the flexibility
heels of a licensing agreement with LG Life Sciences                          to adapt quickly to unexpected changes in the flu.
(LGLS), of Seoul, South Korea, that could open markets in                          The HHS funding will allow the company to hire 20
several emerging countries. The back-to-back news is                          additional scientists and technical staff, a 44 percent
“transformational for the company,” Novavax President and                     increase to its 45-person work force, Shaw said, which will
CEO Rahul Singhvi told investors. “Today, we are from every                   help with increased reporting requirements and trials.
perspective – scientific, financial and commercial – a much                          Using VaxInnate’s Toll-like receptor (TLR) technology,
stronger and more competitive company in the vaccine                          initial trials will evaluate the components and combinations
arena.”                                                                       of what will ultimately be several different pandemic flu
     That strength was reflected in the value of Novavax                       vaccines and a seasonal quadrivalent flu vaccine.
(NASDAQ:NVAX) shares, which jumped nearly 14 percent, or                           The TLR technology genetically fuses vaccine antigens
36 cents, Tuesday, closing at $2.96.                                          to the bacterial protein flagellin, producing a synthetic
     Piper Jaffray’s Edward Tenthoff maintained his                           product that can be quickly and inexpensively reproduced.
overweight rating for Novavax but increased the share                         Unlike traditional egg-based vaccines, VaxInnate’s vaccines
price target from $3 to $4.                                                   can be frozen and stored for long periods of time, Shaw
     The HHS contracts, awarded through its Biomedical                        explained.
Advanced Research and Development Authority, are part                              Because the vaccine is synthetic, VaxInnate doesn’t
of a national pandemic vaccine preparedness strategy                          have the burden of growing the influenza virus needed for
that includes the advanced development of new types of                        traditional vaccines.
influenza vaccines. The strategy also calls for expanding                           The technology “sort of short circuits many of the
and diversifying domestic influenza vaccine production                         issues” involved with egg-based vaccines, Shaw added.
and establishing and testing stockpiles of pre-pandemic                            For instance, using its technology, VaxInnate can turn
vaccine.                                                                      around a new strain in less than three months and produce
     Under its contract, Novavax plans to conduct a dose-                     millions of doses in a single six-day production run.
confirming Phase II trial of its seasonal vaccine in 500-                           VaxInnate already completed a series of Phase I/II trials
600 subjects in the last half of the year. A Phase III study                  using VAX 125 and VAX128, prototype vaccines for both
is expected to begin late next year, with a biologic license                  seasonal and pandemic Type A1 flu vaccines.
application submitted to the FDA in 2014, said Trizzino.                           The most recent trial, involving three forms of the
     The company also will develop a detailed plan for a                      VAX128 vaccine, confirmed the safety and efficacy of the
manufacturing facility that has the capability to produce                     vaccine in elderly subjects, who are less responsive to flu
finished vaccine within 12 weeks and at least 50 million                       vaccines due to the effects of aging on the immune system.
doses within six months of an influenza pandemic                               (See BioWorld Today, May 7, 2009.)
declaration.                                                                       Under its contract with HHS, VaxInnate will be able to
     As for the licensing agreement, Novavax granted                          broaden the flu strains its technology can address, Rudnick
LGLS an exclusive license to manufacture, develop and                         noted. ■
commercialize influenza vaccines using its recombinant
VLP technology in South Korea and a nonexclusive license                                      BioWorld is now on Twitter!
in Africa, Central America, South America and other parts                            Stay Connected, Follow Us on Twitter!
of Asia.                                                                                        www.twitter.com/bioworld

               To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.
                        Copyright © 2011 AHC Media. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
WEDNESDAY, MARCH 2, 201 1                                        BIOWORLD® TODAY                                                           PAGE 6 OF 8

Financings Roundup                                                            capital and other general corporate purposes.
Continued from page 1                                                              Piper Jaffray & Co. served as sole lead placement agent,
     Shares of Tengion (NASDAQ:TNGN) fell 23 cents                            while Leerink Swann LLC served as co-placement agent.
Tuesday to close at $2.49.                                                         In other financings news:
     The stock traded as high as $5.51 last month – trading                        • NeuroPhage Pharmaceuticals Inc., of Cambridge,
volume peaked at 25 times the average in mid-February –                       Mass., said it secured $12.4 million in Series B financing.
at least in part on rumors that the firm was in acquisition                    The funding will be used for Phase I trials of its Alzheimer’s
negotiations.                                                                 candidate, NPT001 . Mérieux Développement was the lead
     Only days later, Tengion confirmed that it had been in                    investor, with Shire LLC participating as a new investor.
talks about a stock-for-stock merger with an undisclosed                      NeuroPhage’s total capital raised since 2007 is $19.6
publicly traded company, but said the potential acquirer                      million.
ended negotiations due to the unexpected increase in                               • RXi Pharmaceuticals Corp., of Worcester, Mass.,
trading price and volume.                                                     priced a public offering of 6 million units at $1 .35 each for
     Tengion had about $12.5 million on its balance sheet                     gross proceeds of $8. 1 million. Each unit consists of one
as of Sept. 30, which it said would carry the firm into April.                 share of common stock, a 13-month warrant to purchase
If a possible sale or alternative financing transaction had                    0.50 of a share of stock at an exercise price of $1 .70 each
not come through, the company might have had to look at                       and a five-year warrant to purchase 0.50 of a share at an
winding down operations only a year after it succeeded in                     exercise price of $1 .87 per share. The RNAi firm expects net
going public.                                                                 proceeds to total about $7.3 million and said those funds
     Though it had to take a haircut on the price, Tengion’s                  will be used for general corporate purposes. Lazard Capital
initial public offering (IPO) was a major coup for the life                   Markets LLC is acting as sole book-running manager, and
sciences industry, as the first true early stage biotech to                    Roth Capital Partners LLC is acting as co-manager. Shares
squeeze out of the current IPO window. Unfortunately, the                     of RXi (NASDAQ:RXII) fell 47 cents, or 27.7 percent, to close
$30 million offering was less than the firm had hoped to                       Tuesday at $1 .23. ■
raise, forcing it to return to investors for more cash. (See
BioWorld Today, April 12, 2010.)
     And Tengion isn’t alone. Other new market entrants
have had to seek cash shortly after completing IPOs.                                       Clinic Roundup
Anthera Pharmaceuticals Inc. and AVEO Pharmaceuticals
Inc., for instance, both completed PIPE financings about six                        • Neuralstem Inc., of Rockville, Md., dosed its first
months after going public. (See BioWorld Today, Sept. 22,                     subject in a Phase Ia trial of NSI-189, for major depressive
2010, and Nov. 1 , 2010.)                                                     disorder. The company said that NSI-189 stimulates new
     Proceeds from Tengion’s PIPE are expected to fund                        neuron growth to restore brain physiology. In the trial,
R&D activities, primarily related to its Neo-Urinary Conduit                  healthy volunteers will be given a single oral dose of NsI-
and Neo-Kidney Augment programs. Both are based on the                        189. After the maximum tolerated single dose is determined,
company’s platform, which involves isolating progenitor                       Phase Ib will commence with escalating daily doses for 28
cells from a patient’s tissue sample, then expanding those                    days in patients with major depressive disorder.
cells and placing them on a bioabsorbable scaffold within                          • NPS Pharmaceuticals Inc., of Bedminster, N.J., has
a bioreactor to grow a new organ. That new organ is then                      randomized its last patient in a Phase III trial of NPS558
implanted into the patient.                                                   for hypoparathyroidism. NPS558 is a bioengineered form
     The Neo-Urinary Conduit is the lead program. It’s                        of human parathyroid hormone. The study, designated
designed to use smooth muscle cells to grow tissue for                        REPLACE, includes a total of 135 patients. Top line results are
bladder cancer patients who need urinary diversion after                      expected by the end of the year.
bladder removal. Tengion has initiated a five-person trial                          • Poniard Pharmaceuticals Inc., of San Francisco,
and, in November, completed the one-month postoperative                       received approval from the Chinese State Food and Drug
clinical assessment for the first patient. That study is aimed                 Administration to conduct two Phase III trials of its lead
at providing safety data and helping investigators optimize                   product candidate, picoplatin, in the treatment of second-
the surgical technique.                                                       line small-cell lung cancer (SCLC) and second-line ovarian
     In preclinical development, Tengion has Neo-Kidney                       cancer. The approval will allow Poniard to include Chinese
Augment, which is designed to improve renal function and                      clinical sites in global registration trials within those disease
prevent or delay dialysis or transplant. Other early stage                    settings. Picoplatin, a platinum-based chemotherapeutic
programs include Neo-GI Augment for intestinal issues and                     agent, has demonstrated promising clinical activity in SCLC
Neo-Vessel Replacement as a graft alternative.                                and ovarian cancer, the company said. Shares of Poniard
     Remaining funds from the offering, set to close prior to                 (NASDAQ:PARD) gained 5 cents, or 14.3 percent, to close at
March 4, will go toward debt repayment and for working                        40 cents Tuesday.

               To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.
                        Copyright © 2011 AHC Media. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
WEDNESDAY, MARCH 2, 201 1                                        BIOWORLD® TODAY                                                           PAGE 7 OF 8

                                                                                   • Shareholders of Insmed Inc., of Richmond, Va.,
        Other News To Note                                                    approved a stock conversion and a 1-for-10 reverse stock
                                                                              split of the company’s common stock. As a result, 91 .7
    • Geron Corp., of Menlo Park, Calif., reported                            million outstanding shares of Series B preferred stock were
preclinical study data showing positive effects of GRNCM1 ,                   immediately converted into common stock. Insmed intends
the company’s cardiomyocyte product derived from                              to effect the reverse stock split as of the close of business
human embryonic stem cells, in a small animal model of                        Wednesday. In December, the company was given until
acute heart damage. Administering GRNCM1 by injection                         June 13 to comply with Nasdaq’s $1 minimum bid price rule.
into the heart resulted in greater resistance to induced                      Shares of Insmed (NASDAQ:INSM) lost 4 cents Tuesday, to
arrhythmias, halted adverse cardiac remodeling and                            close at 50 cents.
preserved mechanical function compared to controls. The                            • IRX Therapeutics Inc., of New York, signed a
results suggested that GRNCM1 positively affects cardiac                      research collaboration with an undisclosed research-
function through several mechanisms, leading to overall                       based pharmaceutical firm in which tumor specimens from
increased cardiac output and decreased arrhythmias in the                     subjects treated with IRX-2 and control subjects will be
acute infarct setting. Geron is developing GRNCM1 for the                     analyzed by the collaborating company using gene analysis
treatment of myocardial disease. The data were presented                      technology. The goal is to characterize the action of IRX-
at the Keystone Symposium on Mechanisms of Cardiac                            2 immunotherapy at the molecular level and assess the
Growth, Death and Regeneration in Colorado.                                   potential effects of the drug on the tumor microenvironment.
                                                                              IRX-2 was tested in a Phase II trial enrolling patients with
                                                                              newly diagnosed head and neck squamous cell cancer who
     Wondering What You                                                       received IRX-2 prior to surgery.
                                                                                   • KemPharm Inc., of North Liberty, Iowa, filed an
  Missed in BioWorld Insight?                                                 answer and counterclaims against Shire LLC, a subsidiary
                                                                              of Shire plc, of Dublin, Ireland. The counterclaims were
            Reverse Merger Interest Dims                                      filed in response to a lawsuit filed in Virginia on Sept.
             as IPO Window Creaks Open                                        30, 2010, by Shire against KemPharm and Travis Mickle,
       It became the exit du jour two years ago when the                      KemPharm’s president and CEO, alleging breach of contract
  initial public offering window slammed shut, but now                        and intentional interference with contract in relation to
  the reverse merger seems to have regained its previous                      Mickle’s prior employment with New River Pharmaceuticals,
  less-than-favorable reputation. To find out whether that                     which Shire acquired in 2007. KemPharm’s answer denies
  reputation is warranted, BioWorld Insight takes a look                      the allegations of Shire’s complaint, raises affirmative
  back at some of the highly touted reverse merger deals                      defenses and makes claims for unfair competition, antitrust
  of 2007 – 2008 and finds out where they are now.                             violations and other relief. The antitrust claims assert that
                                                                              the Shire lawsuit is baseless and designed to interfere with
             Genzyme Aces in Hand May                                         KemPharm’s business. (See BioWorld Today, Feb. 21 , 2007.)
            Ward Off Pharma Culture War                                            • MediGene AG, of Martinsried, Germany, completed the
      Sanofi-Aventis SA said it intends to preserve the                        transfer of exclusive European rights to Eligard (leuprolide
  biotech culture at Genzyme Corp. after the acquisition,                     acetate) for the treatment of hormone-dependent prostate
  but can suit coats and lab coats really get along? As the                   cancer to Astellas Pharma Europe Ltd., of London, part
  large-cap biotech players fold one by one, Genzyme                          of Astellas Pharma Inc. The transaction triggered a second
  may have the cards to stay in the game.                                     milestone payment to MediGene, in the amount of €15 million
                                                                              (US$20.65 million). Effective March 1 MediGene also will
             Calistoga Buyout Spotlights                                      receive a 2 percent share in net European sales of Eligard. The
             Selective Kinase Perception                                      transfer of rights terminated MediGene’s costs and obligations
      Kinase inhibition has been a biotech staple for the                     associated with future supplies of Eligard to Astellas.
  past decade, but the trick has been trying to create small                       • Oncothyreon Inc., of Seattle, reported preclinical
  molecules selective enough to avoid off-target effects.                     data demonstrated the effect of its PX-866, a small-molecule
  Recent deals such as Gilead Sciences Inc.’s buyout of                       compound, and its metabolite as an irreversible inhibitor
  Calistoga Pharmaceuticals Inc. suggest the industry is                      of phosphatidylinositol 3-kinase (PI3K). The data were
  making impressive headway.                                                  presented at an American Association of Cancer Research
                                                                              special conference on targeting PI3K/mTOR signaling.
     Take BioWorld Insight for a test drive. Call (404)                       Oncothyreon is conducting a broad development program
  262-5476 or (800) 688-2421 and mention editor Trista                        of PX-866, including trials evaluating the compound as
  Morrison for a free trial subscription.                                     a single agent and in combination with other agents in
                                                                              multiple cancer types.

               To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.
                        Copyright © 2011 AHC Media. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
WEDNESDAY, MARCH 2, 201 1                                        BIOWORLD® TODAY                                                           PAGE 8 OF 8



        Other News To Note                                                                 Clinic Roundup
    • Pfizer Inc., of New York, completed its purchase of                           • Seattle Genetics Inc., of Bothell, Wash., and Millennium,
King Pharmaceuticals Inc., of Bristol, Tenn., for $14.25                      of Cambridge, Mass., a unit of the Takeda Pharmaceutical
per share, or about $3.6 billion. King is now a wholly owned                  Co. Ltd., initiated a Phase I trial of brentuximab vedotin in
subsidiary of Pfizer. (See BioWorld Today, Oct. 13, 2010.)                     combination with chemotherapy for the treatment of newly
    • Pluristem Therapeutics Inc., of Haifa, Israel, and                      diagnosed systemic anaplastic large cell lymphoma patients.
the Berlin-Brandenburg Center for Regenerative Therapies,                     The dose-escalation trial will evaluate brentuximab vedotin,
in cooperation with the Charite-University of Medicine in                     an antibody-drug conjugate, when administered sequentially
Berlin, reported positive results from a preclinical study                    or in combination with multi-agent, front-line chemotherapy
demonstrating that local administration of Pluristem’s                        regimens. The study is expected to enroll up to 60 patients at
PLX cells following muscle injury resulted in significant                      multiple centers in Europe and the U.S.
improvement in the recovery of muscle function when                                • Syndax Pharmaceuticals Inc., of Waltham, Mass.,
compared with the control group. Study data indicated                         will sponsor a Phase II study of its breast cancer candidate,
PLX cells can be used in accidental injuries, such as athletic                entinostat, in postmenopausal women with operable triple
injuries, as well as intentional injuries, such as the incision               negative breast cancer, with the goal of reprogramming
of skeletal muscle during surgery. Based on the findings,                      tumors to express estrogen receptor, thereby becoming
Pluristem plans to move ahead with clinical trials for muscle                 sensitive to hormonal therapy. In a preclinical study in
injury indications, which will be conducted in addition to                    animals, it was established that entinostat induces re-
the company’s anticipated Phase II/III trial using PLX-PAD for                expression of extrogen receptor and aromatase in triple
the treatment of critical limb ischemia. Earlier this year, the               negative breast cancer cell lines. Those cells are then
company raised $36 million in a public offering to finance                     sensitive to aromatase inhibitor. That study was published
that trial. (See BioWorld Today, Jan. 28, 2011 .)                             in the March 1 , 2011 , issue of Cancer Research.
    • Precision Therapeutics Inc., of Pittsburgh, and                              • Tobira Therapeutics Inc., of Princeton, N.J., said
Med BioGene Inc., of Vancouver, British Columbia, signed                      that single-dose cenicriviroc had no dose-limiting toxicity,
a commercialization, license and research reimbursement                       predictable pharmacokinetics and good oral bioavailability
agreement providing Precision with exclusive global rights                    in a Phase I trial for HIV. The drug was given to healthy
to develop and commercialize LungExpress Dx, a gene                           volunteers in doses from 10 mg to 800 mg. Data were
expression-based test designed to improve staging and                         presented at the 2011 Conference on Retroviruses and
better identify mortality risks for patients with early stage                 Opportunistic Infections being held in Boston this week.
non-small-cell lung cancer following surgical removal of                      The company plans to initiate Phase IIb studies in the
their tumors.                                                                 second quarter.




           B IO W ORLD P ERSPECTIVES
            A free, weekly e-zine offering unique viewpoints
           on developments within the biotechnology industry.
                 Sign-up today and get a fresh outlook
                on topics that you can’t find elsewhere!

                    Go to BioWorld.com and click on “Perspectives”!


               To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.
                        Copyright © 2011 AHC Media. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com

More Related Content

Similar to Bwt03022011

Bwt05212010
Bwt05212010Bwt05212010
Bwt05212010penneyh
 
Biotechnology Power Presentation
Biotechnology Power PresentationBiotechnology Power Presentation
Biotechnology Power PresentationAjit Singh
 
Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021
Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021
Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021Levi Shapiro
 
Genetic Engineering And The Canadian Regulation
Genetic Engineering And The Canadian RegulationGenetic Engineering And The Canadian Regulation
Genetic Engineering And The Canadian RegulationAmanda Marie
 
Probiotics and prebiotics nrgastro.2014.66
Probiotics and prebiotics nrgastro.2014.66Probiotics and prebiotics nrgastro.2014.66
Probiotics and prebiotics nrgastro.2014.66Elsa von Licy
 
5 companies in the wound healing market to watch for in 2019
5 companies in the wound healing market to watch for in 20195 companies in the wound healing market to watch for in 2019
5 companies in the wound healing market to watch for in 2019Avi Surana
 
Science and Tech question for UPSC prelims
Science and Tech question for UPSC prelimsScience and Tech question for UPSC prelims
Science and Tech question for UPSC prelimsfaizankhan260690
 
Designing of drug delivery system for biotechnology products considering stab...
Designing of drug delivery system for biotechnology products considering stab...Designing of drug delivery system for biotechnology products considering stab...
Designing of drug delivery system for biotechnology products considering stab...Smaranika Rahman
 
Cell magazine stem cell biotech (feb 2008)
Cell magazine   stem cell biotech (feb 2008)Cell magazine   stem cell biotech (feb 2008)
Cell magazine stem cell biotech (feb 2008)ProteusVenturePartners
 
Merc &Amp; Vioxx Case
Merc &Amp; Vioxx CaseMerc &Amp; Vioxx Case
Merc &Amp; Vioxx CaseLaura Martin
 
Essay On Biotechnology
Essay On BiotechnologyEssay On Biotechnology
Essay On BiotechnologyMichelle Adams
 
Life & health Sciences Horizon Panel Report
Life & health Sciences Horizon Panel ReportLife & health Sciences Horizon Panel Report
Life & health Sciences Horizon Panel ReportEuroBioForum
 
Lean launch pad for Life Sciences and Health Care
Lean launch pad for Life Sciences and Health CareLean launch pad for Life Sciences and Health Care
Lean launch pad for Life Sciences and Health CareStanford University
 
Most emerging biotech companies to watch.pdf
Most emerging biotech companies to watch.pdfMost emerging biotech companies to watch.pdf
Most emerging biotech companies to watch.pdfInsightsSuccess4
 

Similar to Bwt03022011 (20)

Bwt05212010
Bwt05212010Bwt05212010
Bwt05212010
 
Biotechnology Power Presentation
Biotechnology Power PresentationBiotechnology Power Presentation
Biotechnology Power Presentation
 
Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021
Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021
Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021
 
Genetic Engineering And The Canadian Regulation
Genetic Engineering And The Canadian RegulationGenetic Engineering And The Canadian Regulation
Genetic Engineering And The Canadian Regulation
 
B2 novartis
B2 novartisB2 novartis
B2 novartis
 
MedTech Dealmakers, October 2015
MedTech Dealmakers, October 2015MedTech Dealmakers, October 2015
MedTech Dealmakers, October 2015
 
Probiotics and prebiotics nrgastro.2014.66
Probiotics and prebiotics nrgastro.2014.66Probiotics and prebiotics nrgastro.2014.66
Probiotics and prebiotics nrgastro.2014.66
 
5 companies in the wound healing market to watch for in 2019
5 companies in the wound healing market to watch for in 20195 companies in the wound healing market to watch for in 2019
5 companies in the wound healing market to watch for in 2019
 
Science and Tech question for UPSC prelims
Science and Tech question for UPSC prelimsScience and Tech question for UPSC prelims
Science and Tech question for UPSC prelims
 
CNDO 11-12-11 BioWorld Insight
CNDO 11-12-11 BioWorld InsightCNDO 11-12-11 BioWorld Insight
CNDO 11-12-11 BioWorld Insight
 
BioPharma Dealmakers_September 2015
BioPharma Dealmakers_September 2015BioPharma Dealmakers_September 2015
BioPharma Dealmakers_September 2015
 
Biosimilars
Biosimilars Biosimilars
Biosimilars
 
Designing of drug delivery system for biotechnology products considering stab...
Designing of drug delivery system for biotechnology products considering stab...Designing of drug delivery system for biotechnology products considering stab...
Designing of drug delivery system for biotechnology products considering stab...
 
Cell magazine stem cell biotech (feb 2008)
Cell magazine   stem cell biotech (feb 2008)Cell magazine   stem cell biotech (feb 2008)
Cell magazine stem cell biotech (feb 2008)
 
Merc &Amp; Vioxx Case
Merc &Amp; Vioxx CaseMerc &Amp; Vioxx Case
Merc &Amp; Vioxx Case
 
Essay On Biotechnology
Essay On BiotechnologyEssay On Biotechnology
Essay On Biotechnology
 
Life & health Sciences Horizon Panel Report
Life & health Sciences Horizon Panel ReportLife & health Sciences Horizon Panel Report
Life & health Sciences Horizon Panel Report
 
Lean launch pad for Life Sciences and Health Care
Lean launch pad for Life Sciences and Health CareLean launch pad for Life Sciences and Health Care
Lean launch pad for Life Sciences and Health Care
 
Most emerging biotech companies to watch.pdf
Most emerging biotech companies to watch.pdfMost emerging biotech companies to watch.pdf
Most emerging biotech companies to watch.pdf
 
biotech
biotechbiotech
biotech
 

Bwt03022011

  • 1. BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS WEDNESDAY VOLUME 22 , NO. 41 MARCH 2, 201 1 PAGE 1 OF 8 ‘Buy American’ FDA OKs Narrower Indication Daiichi Sankyo Bolsters Pipe for Forest Lab’s COPD Drug with $935M Plexxikon Buy By Marie Powers By Tom Wall BioWorld Today Contributing Writer Staff Writer After a long and winding road, the FDA has at last given In the latest acquisition of a U.S. biotech with promising Forest Laboratories Inc. the green light to market Daliresp oncology offerings by a Japanese company, Daiichi Sankyo (roflumilast) in the U.S. to reduce the risk of chronic Co. Ltd., of Tokyo, bought Plexxikon Inc., of Berkeley, Calif., obstructive pulmonary disease (COPD) exacerbations and its promising melanoma drug PLX4032, for $805 million in patients with severe COPD associated with chronic up front and near-term milestones of $130 million linked to bronchitis and a history of such flare-ups, which may approval of PLX4032. include breathlessness, chronic cough and excessive In recent years, Japanese drugmakers have made a production of phlegm leading to medical intervention, series of major U.S. oncology buys, including Eisai Co.’s $205 including hospitalization. million September 2006 purchase of Ligand Pharmaceuticals In 2009, New York-based Forest licensed the drug – Inc.’s three-drug cancer portfolio, a $325 million buyout of marketed as Daxas in the European Union and Canada Morphotek in March 2007 and, earlier this year, $200 million – from privately held Nycomed GmbH, of Zurich, in research funding to start-up H3 Biomedicine; Takeda Switzerland, in a deal potentially worth more than $500 Pharmaceutical Co.’s $8.8 billion purchase of Millennium million. (See BioWorld Today, Aug. 11 , 2009.) Pharmaceuticals Inc. in April 2008; and Astellas Pharma Nycomed had initially submitted the new drug See Plexxikon, Page 2 See Forest, Page 4 Novavax, VaxInnate Get Financings Roundup Welcome Shot in the Arm Investors to the Rescue as By Mari Serebrov Tengion Pulls in $31M PIPE Washington Editor By Jennifer Boggs WASHINGTON – Two government contracts that could be Assistant Managing Editor worth up to nearly $200 million each will inoculate Novavax After a roller coaster February, in which shares of Inc. and VaxInnate Inc. against some of the financial risks Tengion Inc. rose on buyout speculation only to fall after involved in getting their recombinant influenza vaccines the surge in trading activity scared off a potential acquirer, through clinical development. investors of the East Norriton, Pa.-based regenerative The cost-reimbursable, milestone-based contracts, medicine firm have stepped up with some much-needed awarded by the Department of Health and Human Services financing. (HHS), are for three years with a possible two-year extension. Tengion is bringing in $31 .4 million in a PIPE transaction Novavax, of Rockville, Md., will receive $97 million over in exchange for issuing about 1 1 . 1 million shares of common the first three years, which is enough to bring its seasonal stock and warrants to purchase about 10.5 million shares influenza recombinant virus-like particle (VLP) vaccine to certain investors. One of those investors is Medtronic through late-stage trials to FDA licensure, John Trizzino, Inc., a Minneapolis-based medical device company that Novavax senior vice president of business development, picked up, in exchange, a right of first refusal on the told investors Tuesday. preclinical Neo-Kidney Augment program through Oct. 31, If the extension is granted, the total contract would 2013. See Influenza, Page 5 See Financings Roundup, Page 6 INSIDE: OTHER NEWS TO NOTE: GERON, INSMED, IRX THERAPEUTICS, KENPHARM .....7 CLINIC ROUNDUP: SEATTLE GENETICS, SYNDAX, TOBIRA THERAPEUTICS ...........8 To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476. Copyright © 2011 AHC Media. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
  • 2. WEDNESDAY, MARCH 2, 201 1 BIOWORLD® TODAY PAGE 2 OF 8 Plexxikon Continued from page 1 Inc.’s $4 billion acquisition of OSI in May 2010 and several Coming Thursday in deals leading up to it. BioWorld Perspectives: The pattern is not a coincidence, Plexxikon CEO K. Peter Hirth told BioWorld Today, but rather how Japanese ‘All My Clones,’ companies must compete because of a shortage of biotech BioWorld’s Biotech-Themed Soap Opera innovation in Japan. “It’s particularly true in oncology,” Hirth said. “The In this week’s “All My Clones,” read about Cappuccino innovation gap in Japanese pharma in the last 10 years is just Pharmaceuticals’ plans to investigate placebos and mind boggling. There is not enough innovation happening some unethical actions by board members. If you in Japan by itself. They have to buy it. Biotech did not take off missed previous episodes of BioWorld’s biotech-themed in Japan. It has been a big challenge for the Japanese.” soap opera, look to the top of the story for a link to the PLX4032 captured the attention of the cancer world “All My Clones” archives. during the past year and a half. Most recently, an interim analysis of a Phase III trial released in January showed both BioWorld Perspectives is a weekly e-zine that an overall survival benefit and a progression-free survival offers unique viewpoints on developments within benefit for patients taking the drug as a first-line agent. (See the biotechnology industry. And the best part is, it’s BioWorld Today, Jan. 20, 2011 , and Nov. 8, 2010.) completely free. Opt-in at www.bioworld.com. The 675-patient BRIM 3 study was the first where PLX4032, which also goes by the name RG7204, was used as a first-line agent for BRAF mutation positive metastatic melanoma. Patients were randomized to receive either oral PLX4032 twice daily, or the current standard of care, which consists of intravenous dacarbazine every three weeks. Stock Movers Hirth said at the time the data were so strong that the study 03/01/1 1 was terminated early, and patients in the control arm have Company Stock Change been given the option to cross over onto PLX4032. Plexxikon, a privately held firm, and development Nasdaq Biotechnology -$6.44 -0.7% partner Roche AG, planned to file for market approval Novavax Inc. +$0.36 +13.9% in the U.S. and Europe this year, along with a filing for the companion diagnostic also being co-developed by the Repros Therapeutics Inc. +$1 .29 +28.7% partners. It is an extremely quick progression. The Phase I RXi Pharmaceuticals Corp. -$0.47 -27.7% trial of PLX4032 began in December 2006. The results of that Vivus Inc. -$0.83 -10.9% trial, which were published in 2010, prompted Plexxikon and Roche to move the drug directly into pivotal testing. The first patient was enrolled in the BRIM3 study in January 2010. (Biotechs showing significant stock changes Tuesday) See Plexxikon, Page 3 SUBSCRIBER INFORMATION BioWorld® Today (ISSN# 1541-0595) is published every business day by AHC Media, 3525 Piedmont Road, Building Six, Suite 400, Atlanta, GA 30305 U.S.A. Opinions expressed are not necessarily those Please call (800) 688-2421 to subscribe or if of this publication. Mention of products or services does not constitute endorsement. BioWorld® and Bio- you have fax transmission problems. Outside World® Today are trademarks of AHC Media, a Thompson Publishing Group company. Copyright © 2011 U.S. and Canada, call (404) 262-5476. Our AHC Media. All Rights Reserved. No part of this publication may be reproduced without the written con- customer service hours are 8:30 a.m. to 6:00 sent of AHC Media. (GST Registration Number R128870672). p.m. EST. Lynn Yoffee, (404) 262-5408 ATLANTA NEWSROOM: Managing Editor: Lynn Yoffee. Assistant Managing Editor: Jennifer Boggs. Jennifer Boggs, (404) 262-5427 Senior Staff Writer: Karen Pihl-Carey. Senior Production Editor: Ann Duncan. Staff Writer: Tom Wall. Anette Breindl, (518) 595-4041 Trista Morrison, (858) 901-4785 WASHINGTON BUREAU: Washington Editor: Mari Serebrov. Mari Serebrov, (703) 678-7376 WEST COAST BUREAU: Staff Writer: Trista Morrison. Tom Wall, (404) 262-5417 EAST COAST BUREAU: Science Editor: Anette Breindl. BUSINESS OFFICE: Senior Vice President/Group Publisher: Donald R. Johnston. Senior Vice President/Group Publisher: Director of Product Management: Jane Cazzorla. Donald R. Johnston, (404) 262-5439 Marketing Manager: Sarah Cross. Internet: http://www.bioworld.com Account Representatives: Matt Hartzog, Chris Wiley, Scott Robinson. DISPLAY ADVERTISING: For ad rates and information, please call Stephen Vance at (404) 262-5511 or email him at stephen.vance@ahcmedia.com. REPRINTS: For photocopy rights or reprints, call our reprints department at (404) 262-5479. PRESS MATERIALS: Send all press releases and related information to newsdesk@bioworld.com.
  • 3. WEDNESDAY, MARCH 2, 201 1 BIOWORLD® TODAY PAGE 3 OF 8 Plexxikon for pancreatic cancer. (See BioWorld Today, Sept. 11, 2006, and Continued from page 2 March 23, 2007.) Plexxikon has an agreement to co-promote PLX4032 In January of this year, Eisai Inc., of Woodcliff Lake, N.J., in the U.S. with Roche’s U.S. commercial oncology the U.S. pharmaceutical operation of Tokyo-based Eisai Co. unit, Genentech. Daiichi Sankyo will retain the U.S. co- pledged as much as $200 million in research funding to promotion rights for PLX4032. Hirth said that he expects start-up H3 Biomedicine, of Cambridge, Mass., which hopes co-promotion will be, “pretty straightforward. It will just to develop oncology treatments genetically tailored to be shared. Everybody knows everybody, and everybody is patients’ cancers. (See BioWorld Today, Jan. 31 , 2011 .) comfortable.” Takeda, of Osaka, acquired Millennium Pharmaceuticals Hirth said Plexxikon will continue on with similar Inc., of Cambridge, Mass., and its lucrative Velcade multiple staff and budget. “They like the way we have developed myeloma product in April 2008 for $8.8 billion, renaming projects, and they expect to get a number of additional the company Millennium: The Takeda Oncology Co. (See development candidates,” he said, describing the 40-plus BioWorld Today, April 11, 2008.) person Plexxikon team as “good size, working well, a fine- Astellas, of Tokyo, bought OSI, of Melville, N.Y., for $4 tuned racing engine.” billion in May 2010, boosting its oncology franchise and PLX4032, an orally active kinase inhibitor that targets adding OSI’s blockbuster cancer drug Tarceva (erlotinib) as an activating BRAF mutation, is also an example of the well as a U.S. sales force, a pipeline of small molecules and power of personalized medicine. The drug is being co- discovery capabilities. (See BioWorld Today, May 18, 2010.) developed with a diagnostic test to identify patients whose A series of smaller deals led up to the OSI acquisition. tumors carry the V600 mutation. Such mutations account In December 2007 Astellas bought Agensys Inc., of Santa for about half of all melanoma cases. Monica, Calif., and a pipeline of early clinical-stage anticancer The extremely rapid hurtle down the clinical antibodies for $537 million; licensed prostate cancer drug development path also means that the conclusions about MDV3100 in a $765 million deal with Medivation Inc., of PLX4032’s safety and efficacy are based on relatively San Francisco, in October 2009; and in December 2009 got few patients, and relatively few clinical events. Such acute myeloid leukemia drug AC220 in a potential $390 small numbers and statistics can be shaky, but Plexxikon million deal with Ambit Biosciences Corp., of San Diego. executives have said that because of the strength of the If U.S. oncology biotechs have attracted attention from data, they are not concerned that the sample size is small. Japanese companies, so too, have selective kinase inhibitors Melanoma has proved a tough disease for drug been in the spotlight of late. (See BioWorld Insight, Feb. 28, developers in the past, with notable failures such as Genta 2011 .) Inc.’s Bcl-2 targeting antisense drug Genasense (oblimersen) Gilead Sciences Inc.’s recent buyout of Calistoga and tyrosine kinase inhibitor Nexavar (sorafenib) from Pharmaceuticals Inc. for $375 million in cash and up to Onyx Pharmaceuticals Inc. and Bayer AG. But there have $225 million in milestones for rights to PI3K delta isoform been bright spots in the space of late, with Bristol-Myers CAL-101 underscores the enthusiasm for small-molecule Squibb Co.’s ipilimumab, acquired through its acquisition of kinase inhibition. A week earlier AVEO Pharmaceuticals Inc. Medarex Inc., showing promising survival data in a pivotal signed a potential $1 billion-plus partnership for tivozanib, study. (See BioWorld Today, June 8, 2010, and Nov. 8, 2010.) a Phase III-stage kinase inhibitor targeting VEGFR 1 , 2 and 3. Joji Nakayama, CEO of Daiichi Sankyo Co. Ltd., said (See BioWorld Today, Feb. 17, 2011 , and Feb. 23, 2011 .) in a statement that his company sees the acquisition of Kinase inhibitors have produced blockbusters like Plexxikon as an opportunity to accelerate the building of Gleevec (imatinib, Novartis AG) and near-blockbusters like the company’s oncology franchise. Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer Other major Japanese pharma firms, including Eisai, AG) and Sutent (sunitinib, Pfizer Inc.). ■ Takeda and Astellas, have preceded Daiichi Sankyo with the “buy American” oncology strategy. Eisai in September 2006 purchased a three-drug cancer Clinic Roundup portfolio – Ontak (denileukin diftitox), for cutaneous T-cell lymphoma; Targretin (bexarotene) gel and capsules, also for • Cytheris SA, of Paris, said a Phase IIa study of its CTCL; and Panretin (alitretinoin) gel for Kaposi’s sarcoma, an HIV candidate, CYT109 (interleukin-7), provided evidence AIDS-related skin cancer – from Ligand Pharmaceuticals Inc., of of efficacy and showed that interleukin-7 stimulated the San Diego, for $205 million plus royalties. Eisai next acquired expansion of CD4 and CD8 T cells in peripheral blood. Morphotek, Inc., of Exton, Pa., in March 2007 in a $325 million Those results showed that interleukin-7 was important in buyout. One of a few firms at the time that could make fully stimulating T-cell repopulation of lymphoid tissue in the human monoclonal antibodies in cell culture, Morphotek had GI tract. Cytheris presented the data at the 2011 Conference a pair of clinical-stage drug candidates, MORAb 003, in Phase on Retroviruses and Opportunistic Infections being held in I/II trials for ovarian cancer, and MORAb 009, in Phase I trials Boston this week. To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476. Copyright © 2011 AHC Media. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
  • 4. WEDNESDAY, MARCH 2, 201 1 BIOWORLD® TODAY PAGE 4 OF 8 Forest warnings, but the FDA did not require a black-box warning Continued from page 1 for the drug. application for roflumilast in July 2009 with a proposed The company expects Daliresp to be available to indication as a maintenance treatment of COPD associated wholesalers in the second calendar quarter. with chronic bronchitis in patients at risk of exacerbations. Patients with COPD have largely depended on inhalers Last spring, however, FDA reviewers voiced concerns over to treat symptoms of the disease, so the approval of suicides linked to the drug. (See BioWorld Today, April 6, 2010.) Daliresp “is good news for [Forest] and validates the Subsequently, the FDA’s Pulmonary-Allergy Drugs company as differentiated from a regulatory perspective,” Advisory Committee reversed its earlier endorsement of Leerink Swann Healthcare Equity Research analyst Seamus the drug, voting against the drug’s approval. (See BioWorld Fernandez wrote in a research note. Today, April 8, 2010.) Jefferies & Co. analyst Corey Davis was even Thus, it was hardly a surprise when the agency issued more ebullient, describing Daliresp as “Forest’s most a complete response letter for roflumilast. (See BioWorld underappreciated pipeline drug” and predicting “blockbuster- Today, May 19, 2010.) like potential” for the drug. “We’ve seen the label and it looks In the midst of the FDA’s review, Forest had submitted great,” Davis wrote in a research note. “While there are a new application – too late in the game to be considered some warnings, there are no black-box warnings, no [risk originally by the FDA panel – for the narrower indication evaluation and mitigation strategy], and as we expected, use and a new warning about neuropsychiatric events. At the is being restricted to the most severe patients.” time, analysts suggested the changes would pass muster Though Forest has not disclosed pricing information, with the FDA, which turned out to be the case. Davis expects Daliresp to be priced competitively with Officials at Forest were traveling and did not respond to Spiriva (tiotropium bromide, Pfizer Inc.). requests for an interview. “Because of Daliresp’s unique mechanism of action, we Daliresp, an oral tablet taken once daily, becomes the don’t see it competing directly vs. the inhalers, and as an first FDA-approved selective phosphodiesterase-4 inhibitor. oral med, we see great utility as a potential combo agent,” The compound’s specific mechanism of therapeutic action Davis wrote. Although the “consensus” 2016 Street estimate in COPD is not well defined, but is thought to be related to for Daliresp is $292 million, compared to Jefferies’ $523 the effects of increased intracellular cyclic AMP in lung cells. million estimate, “with Forest likely to go ‘whole hog’ on Forest said the efficacy and safety of Daliresp were the Daliresp launch, and use of the drug likely to move evaluated in eight clinical studies including 9,394 adult upstream into milder COPD patients, we think our estimates patients. Of these, 4,425 were treated with Daliresp 500 mcg. could prove to be conservative,” he added. Two one-year trials enrolled patients with severe COPD Although shares of Forest (NYSE:FRX) gained more than associated with chronic bronchitis, at least one COPD $1 before the market opened Tuesday, sending the stock exacerbation in the previous year and at least a 20 pack- from Monday’s close of $32.40 to $33.64 at Tuesday’s year smoking history. In these trials, long-acting beta- opening bell, the stock lost ground during another brutal agonists and short-acting anti-muscarinics were used by day for the market, closing at $32.02, down 38 cents. ■ 44 percent and 35 percent of patients treated with Daliresp and 45 percent and 37 percent of patients treated with placebo, respectively. Other News To Note One of these trials randomized 1 ,525 patients (765 on Daliresp) and the other randomized 1 ,571 patients (772 on • Genzyme Corp., of Cambridge, Mass., completed Daliresp). Daliresp reduced the rate of moderate or severe the sale of its pharmaceutical intermediates business exacerbations, compared to placebo, by 15 percent in one to International Chemical Investors Group (ICIG). The trial and by 18 percent in the other. acquired business, which includes all but the drug The most common adverse reactions, occurring in less delivery technologies portion, has been renamed Corden than or equal to 10 percent of patients receiving Daliresp Pharma Switzerland LLC and will operate as part of ICIG’s in the eight trials, included diarrhea, nausea, weight loss, pharmaceutical business within the Corden Pharma group. headache, back pain, influenza, insomnia, dizziness and Financial terms are not material to Genzyme and were decreased appetite. Daliresp was associated with an not disclosed. As part of the agreement, Corden Pharma increase in psychiatric adverse reactions (5.9 percent of contracted with Genzyme to provide materials needed patients treated with Daliresp vs. 3.3 percent treated with for the production of eliglustat tartrate, an investigational placebo). During clinical trials, the company said one patient treatment for Gaucher disease Type 1 that’s in Phase III treated with Daliresp committed suicide and two attempted trials, and for the manufacture of other treatments. The suicide, compared to one patient treated with placebo who sale completes the three divestitures announced last year considered suicide. as part of Genzyme’s effort to sharpen its focus on core The risk of suicide is mentioned among the label businesses. (See BioWorld Today, July 22, 2010.) To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476. Copyright © 2011 AHC Media. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
  • 5. WEDNESDAY, MARCH 2, 201 1 BIOWORLD® TODAY PAGE 5 OF 8 Influenza LGLS will be responsible for conducting clinical trials Continued from page 1 and getting the vaccines licensed in these areas. Novavax be $179. 1 million. The additional funding would support will provide technology transfer and manufacturing support three Phase I and II trials of a pandemic H5N1 VLP vaccine, for a manufacturing facility LGLS is building in South Korea. Trizzino added. Novavax will receive an up-front payment with potential VaxInnate, of Cranbury, N.J., will receive $117.9 million milestones, Singhvi said. It also will receive double-digit over the first three years, which can be extended for royalty payments from LGLS’ commercial sales of VLP a total contract value of $196.6 million. The five-year vaccines in South Korea and the emerging markets. Terms funding would enable the privately held company to take of those payments were not disclosed. its seasonal and pandemic influenza vaccines up through At VaxInnate, the HHS contract will “put the company on Phase III development. more solid footing” as it begins the long process of clinical “This gives us the financial security to carry out this trials for its pandemic and seasonal flu vaccines, Seth kind of long-haul development program,” Alan Shaw, Rudnick, a physician, venture partner at Canaan Partners, VaxInnate’s chief scientific officer, told BioWorld Today. “It and board member of VaxInnate, told BioWorld Today. allows us to breathe.” Canaan invested in VaxInnate four years ago to support For Novavax, news of the HHS contract came on the the development of a vaccine technology with the flexibility heels of a licensing agreement with LG Life Sciences to adapt quickly to unexpected changes in the flu. (LGLS), of Seoul, South Korea, that could open markets in The HHS funding will allow the company to hire 20 several emerging countries. The back-to-back news is additional scientists and technical staff, a 44 percent “transformational for the company,” Novavax President and increase to its 45-person work force, Shaw said, which will CEO Rahul Singhvi told investors. “Today, we are from every help with increased reporting requirements and trials. perspective – scientific, financial and commercial – a much Using VaxInnate’s Toll-like receptor (TLR) technology, stronger and more competitive company in the vaccine initial trials will evaluate the components and combinations arena.” of what will ultimately be several different pandemic flu That strength was reflected in the value of Novavax vaccines and a seasonal quadrivalent flu vaccine. (NASDAQ:NVAX) shares, which jumped nearly 14 percent, or The TLR technology genetically fuses vaccine antigens 36 cents, Tuesday, closing at $2.96. to the bacterial protein flagellin, producing a synthetic Piper Jaffray’s Edward Tenthoff maintained his product that can be quickly and inexpensively reproduced. overweight rating for Novavax but increased the share Unlike traditional egg-based vaccines, VaxInnate’s vaccines price target from $3 to $4. can be frozen and stored for long periods of time, Shaw The HHS contracts, awarded through its Biomedical explained. Advanced Research and Development Authority, are part Because the vaccine is synthetic, VaxInnate doesn’t of a national pandemic vaccine preparedness strategy have the burden of growing the influenza virus needed for that includes the advanced development of new types of traditional vaccines. influenza vaccines. The strategy also calls for expanding The technology “sort of short circuits many of the and diversifying domestic influenza vaccine production issues” involved with egg-based vaccines, Shaw added. and establishing and testing stockpiles of pre-pandemic For instance, using its technology, VaxInnate can turn vaccine. around a new strain in less than three months and produce Under its contract, Novavax plans to conduct a dose- millions of doses in a single six-day production run. confirming Phase II trial of its seasonal vaccine in 500- VaxInnate already completed a series of Phase I/II trials 600 subjects in the last half of the year. A Phase III study using VAX 125 and VAX128, prototype vaccines for both is expected to begin late next year, with a biologic license seasonal and pandemic Type A1 flu vaccines. application submitted to the FDA in 2014, said Trizzino. The most recent trial, involving three forms of the The company also will develop a detailed plan for a VAX128 vaccine, confirmed the safety and efficacy of the manufacturing facility that has the capability to produce vaccine in elderly subjects, who are less responsive to flu finished vaccine within 12 weeks and at least 50 million vaccines due to the effects of aging on the immune system. doses within six months of an influenza pandemic (See BioWorld Today, May 7, 2009.) declaration. Under its contract with HHS, VaxInnate will be able to As for the licensing agreement, Novavax granted broaden the flu strains its technology can address, Rudnick LGLS an exclusive license to manufacture, develop and noted. ■ commercialize influenza vaccines using its recombinant VLP technology in South Korea and a nonexclusive license BioWorld is now on Twitter! in Africa, Central America, South America and other parts Stay Connected, Follow Us on Twitter! of Asia. www.twitter.com/bioworld To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476. Copyright © 2011 AHC Media. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
  • 6. WEDNESDAY, MARCH 2, 201 1 BIOWORLD® TODAY PAGE 6 OF 8 Financings Roundup capital and other general corporate purposes. Continued from page 1 Piper Jaffray & Co. served as sole lead placement agent, Shares of Tengion (NASDAQ:TNGN) fell 23 cents while Leerink Swann LLC served as co-placement agent. Tuesday to close at $2.49. In other financings news: The stock traded as high as $5.51 last month – trading • NeuroPhage Pharmaceuticals Inc., of Cambridge, volume peaked at 25 times the average in mid-February – Mass., said it secured $12.4 million in Series B financing. at least in part on rumors that the firm was in acquisition The funding will be used for Phase I trials of its Alzheimer’s negotiations. candidate, NPT001 . Mérieux Développement was the lead Only days later, Tengion confirmed that it had been in investor, with Shire LLC participating as a new investor. talks about a stock-for-stock merger with an undisclosed NeuroPhage’s total capital raised since 2007 is $19.6 publicly traded company, but said the potential acquirer million. ended negotiations due to the unexpected increase in • RXi Pharmaceuticals Corp., of Worcester, Mass., trading price and volume. priced a public offering of 6 million units at $1 .35 each for Tengion had about $12.5 million on its balance sheet gross proceeds of $8. 1 million. Each unit consists of one as of Sept. 30, which it said would carry the firm into April. share of common stock, a 13-month warrant to purchase If a possible sale or alternative financing transaction had 0.50 of a share of stock at an exercise price of $1 .70 each not come through, the company might have had to look at and a five-year warrant to purchase 0.50 of a share at an winding down operations only a year after it succeeded in exercise price of $1 .87 per share. The RNAi firm expects net going public. proceeds to total about $7.3 million and said those funds Though it had to take a haircut on the price, Tengion’s will be used for general corporate purposes. Lazard Capital initial public offering (IPO) was a major coup for the life Markets LLC is acting as sole book-running manager, and sciences industry, as the first true early stage biotech to Roth Capital Partners LLC is acting as co-manager. Shares squeeze out of the current IPO window. Unfortunately, the of RXi (NASDAQ:RXII) fell 47 cents, or 27.7 percent, to close $30 million offering was less than the firm had hoped to Tuesday at $1 .23. ■ raise, forcing it to return to investors for more cash. (See BioWorld Today, April 12, 2010.) And Tengion isn’t alone. Other new market entrants have had to seek cash shortly after completing IPOs. Clinic Roundup Anthera Pharmaceuticals Inc. and AVEO Pharmaceuticals Inc., for instance, both completed PIPE financings about six • Neuralstem Inc., of Rockville, Md., dosed its first months after going public. (See BioWorld Today, Sept. 22, subject in a Phase Ia trial of NSI-189, for major depressive 2010, and Nov. 1 , 2010.) disorder. The company said that NSI-189 stimulates new Proceeds from Tengion’s PIPE are expected to fund neuron growth to restore brain physiology. In the trial, R&D activities, primarily related to its Neo-Urinary Conduit healthy volunteers will be given a single oral dose of NsI- and Neo-Kidney Augment programs. Both are based on the 189. After the maximum tolerated single dose is determined, company’s platform, which involves isolating progenitor Phase Ib will commence with escalating daily doses for 28 cells from a patient’s tissue sample, then expanding those days in patients with major depressive disorder. cells and placing them on a bioabsorbable scaffold within • NPS Pharmaceuticals Inc., of Bedminster, N.J., has a bioreactor to grow a new organ. That new organ is then randomized its last patient in a Phase III trial of NPS558 implanted into the patient. for hypoparathyroidism. NPS558 is a bioengineered form The Neo-Urinary Conduit is the lead program. It’s of human parathyroid hormone. The study, designated designed to use smooth muscle cells to grow tissue for REPLACE, includes a total of 135 patients. Top line results are bladder cancer patients who need urinary diversion after expected by the end of the year. bladder removal. Tengion has initiated a five-person trial • Poniard Pharmaceuticals Inc., of San Francisco, and, in November, completed the one-month postoperative received approval from the Chinese State Food and Drug clinical assessment for the first patient. That study is aimed Administration to conduct two Phase III trials of its lead at providing safety data and helping investigators optimize product candidate, picoplatin, in the treatment of second- the surgical technique. line small-cell lung cancer (SCLC) and second-line ovarian In preclinical development, Tengion has Neo-Kidney cancer. The approval will allow Poniard to include Chinese Augment, which is designed to improve renal function and clinical sites in global registration trials within those disease prevent or delay dialysis or transplant. Other early stage settings. Picoplatin, a platinum-based chemotherapeutic programs include Neo-GI Augment for intestinal issues and agent, has demonstrated promising clinical activity in SCLC Neo-Vessel Replacement as a graft alternative. and ovarian cancer, the company said. Shares of Poniard Remaining funds from the offering, set to close prior to (NASDAQ:PARD) gained 5 cents, or 14.3 percent, to close at March 4, will go toward debt repayment and for working 40 cents Tuesday. To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476. Copyright © 2011 AHC Media. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
  • 7. WEDNESDAY, MARCH 2, 201 1 BIOWORLD® TODAY PAGE 7 OF 8 • Shareholders of Insmed Inc., of Richmond, Va., Other News To Note approved a stock conversion and a 1-for-10 reverse stock split of the company’s common stock. As a result, 91 .7 • Geron Corp., of Menlo Park, Calif., reported million outstanding shares of Series B preferred stock were preclinical study data showing positive effects of GRNCM1 , immediately converted into common stock. Insmed intends the company’s cardiomyocyte product derived from to effect the reverse stock split as of the close of business human embryonic stem cells, in a small animal model of Wednesday. In December, the company was given until acute heart damage. Administering GRNCM1 by injection June 13 to comply with Nasdaq’s $1 minimum bid price rule. into the heart resulted in greater resistance to induced Shares of Insmed (NASDAQ:INSM) lost 4 cents Tuesday, to arrhythmias, halted adverse cardiac remodeling and close at 50 cents. preserved mechanical function compared to controls. The • IRX Therapeutics Inc., of New York, signed a results suggested that GRNCM1 positively affects cardiac research collaboration with an undisclosed research- function through several mechanisms, leading to overall based pharmaceutical firm in which tumor specimens from increased cardiac output and decreased arrhythmias in the subjects treated with IRX-2 and control subjects will be acute infarct setting. Geron is developing GRNCM1 for the analyzed by the collaborating company using gene analysis treatment of myocardial disease. The data were presented technology. The goal is to characterize the action of IRX- at the Keystone Symposium on Mechanisms of Cardiac 2 immunotherapy at the molecular level and assess the Growth, Death and Regeneration in Colorado. potential effects of the drug on the tumor microenvironment. IRX-2 was tested in a Phase II trial enrolling patients with newly diagnosed head and neck squamous cell cancer who Wondering What You received IRX-2 prior to surgery. • KemPharm Inc., of North Liberty, Iowa, filed an Missed in BioWorld Insight? answer and counterclaims against Shire LLC, a subsidiary of Shire plc, of Dublin, Ireland. The counterclaims were Reverse Merger Interest Dims filed in response to a lawsuit filed in Virginia on Sept. as IPO Window Creaks Open 30, 2010, by Shire against KemPharm and Travis Mickle, It became the exit du jour two years ago when the KemPharm’s president and CEO, alleging breach of contract initial public offering window slammed shut, but now and intentional interference with contract in relation to the reverse merger seems to have regained its previous Mickle’s prior employment with New River Pharmaceuticals, less-than-favorable reputation. To find out whether that which Shire acquired in 2007. KemPharm’s answer denies reputation is warranted, BioWorld Insight takes a look the allegations of Shire’s complaint, raises affirmative back at some of the highly touted reverse merger deals defenses and makes claims for unfair competition, antitrust of 2007 – 2008 and finds out where they are now. violations and other relief. The antitrust claims assert that the Shire lawsuit is baseless and designed to interfere with Genzyme Aces in Hand May KemPharm’s business. (See BioWorld Today, Feb. 21 , 2007.) Ward Off Pharma Culture War • MediGene AG, of Martinsried, Germany, completed the Sanofi-Aventis SA said it intends to preserve the transfer of exclusive European rights to Eligard (leuprolide biotech culture at Genzyme Corp. after the acquisition, acetate) for the treatment of hormone-dependent prostate but can suit coats and lab coats really get along? As the cancer to Astellas Pharma Europe Ltd., of London, part large-cap biotech players fold one by one, Genzyme of Astellas Pharma Inc. The transaction triggered a second may have the cards to stay in the game. milestone payment to MediGene, in the amount of €15 million (US$20.65 million). Effective March 1 MediGene also will Calistoga Buyout Spotlights receive a 2 percent share in net European sales of Eligard. The Selective Kinase Perception transfer of rights terminated MediGene’s costs and obligations Kinase inhibition has been a biotech staple for the associated with future supplies of Eligard to Astellas. past decade, but the trick has been trying to create small • Oncothyreon Inc., of Seattle, reported preclinical molecules selective enough to avoid off-target effects. data demonstrated the effect of its PX-866, a small-molecule Recent deals such as Gilead Sciences Inc.’s buyout of compound, and its metabolite as an irreversible inhibitor Calistoga Pharmaceuticals Inc. suggest the industry is of phosphatidylinositol 3-kinase (PI3K). The data were making impressive headway. presented at an American Association of Cancer Research special conference on targeting PI3K/mTOR signaling. Take BioWorld Insight for a test drive. Call (404) Oncothyreon is conducting a broad development program 262-5476 or (800) 688-2421 and mention editor Trista of PX-866, including trials evaluating the compound as Morrison for a free trial subscription. a single agent and in combination with other agents in multiple cancer types. To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476. Copyright © 2011 AHC Media. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
  • 8. WEDNESDAY, MARCH 2, 201 1 BIOWORLD® TODAY PAGE 8 OF 8 Other News To Note Clinic Roundup • Pfizer Inc., of New York, completed its purchase of • Seattle Genetics Inc., of Bothell, Wash., and Millennium, King Pharmaceuticals Inc., of Bristol, Tenn., for $14.25 of Cambridge, Mass., a unit of the Takeda Pharmaceutical per share, or about $3.6 billion. King is now a wholly owned Co. Ltd., initiated a Phase I trial of brentuximab vedotin in subsidiary of Pfizer. (See BioWorld Today, Oct. 13, 2010.) combination with chemotherapy for the treatment of newly • Pluristem Therapeutics Inc., of Haifa, Israel, and diagnosed systemic anaplastic large cell lymphoma patients. the Berlin-Brandenburg Center for Regenerative Therapies, The dose-escalation trial will evaluate brentuximab vedotin, in cooperation with the Charite-University of Medicine in an antibody-drug conjugate, when administered sequentially Berlin, reported positive results from a preclinical study or in combination with multi-agent, front-line chemotherapy demonstrating that local administration of Pluristem’s regimens. The study is expected to enroll up to 60 patients at PLX cells following muscle injury resulted in significant multiple centers in Europe and the U.S. improvement in the recovery of muscle function when • Syndax Pharmaceuticals Inc., of Waltham, Mass., compared with the control group. Study data indicated will sponsor a Phase II study of its breast cancer candidate, PLX cells can be used in accidental injuries, such as athletic entinostat, in postmenopausal women with operable triple injuries, as well as intentional injuries, such as the incision negative breast cancer, with the goal of reprogramming of skeletal muscle during surgery. Based on the findings, tumors to express estrogen receptor, thereby becoming Pluristem plans to move ahead with clinical trials for muscle sensitive to hormonal therapy. In a preclinical study in injury indications, which will be conducted in addition to animals, it was established that entinostat induces re- the company’s anticipated Phase II/III trial using PLX-PAD for expression of extrogen receptor and aromatase in triple the treatment of critical limb ischemia. Earlier this year, the negative breast cancer cell lines. Those cells are then company raised $36 million in a public offering to finance sensitive to aromatase inhibitor. That study was published that trial. (See BioWorld Today, Jan. 28, 2011 .) in the March 1 , 2011 , issue of Cancer Research. • Precision Therapeutics Inc., of Pittsburgh, and • Tobira Therapeutics Inc., of Princeton, N.J., said Med BioGene Inc., of Vancouver, British Columbia, signed that single-dose cenicriviroc had no dose-limiting toxicity, a commercialization, license and research reimbursement predictable pharmacokinetics and good oral bioavailability agreement providing Precision with exclusive global rights in a Phase I trial for HIV. The drug was given to healthy to develop and commercialize LungExpress Dx, a gene volunteers in doses from 10 mg to 800 mg. Data were expression-based test designed to improve staging and presented at the 2011 Conference on Retroviruses and better identify mortality risks for patients with early stage Opportunistic Infections being held in Boston this week. non-small-cell lung cancer following surgical removal of The company plans to initiate Phase IIb studies in the their tumors. second quarter. B IO W ORLD P ERSPECTIVES A free, weekly e-zine offering unique viewpoints on developments within the biotechnology industry. Sign-up today and get a fresh outlook on topics that you can’t find elsewhere! Go to BioWorld.com and click on “Perspectives”! To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476. Copyright © 2011 AHC Media. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com